de Wit R et al., 2019-12-26: CARD randomised 255 men who had already received docetaxel and one androgen-receptor inhibitor to cabazitaxel or the alternative inhibitor. Cabazitaxel improved imaging-based progression-free survival (8.0 vs 3.7 months) and overall survival (13.6 vs 11.0 months; HR 0.64), with grade 3+ adverse events in 56.3% vs 52.4%.
The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).
Abstract (RESULTS)
de Wit R et al., 2019-12-26: CARD randomised 255 men who had already received docetaxel and one androgen-receptor inhibitor to cabazitaxel or the alternative inhibitor. Cabazitaxel improved imaging-based progression-free survival (8.0 vs 3.7 months) and overall survival (13.6 vs 11.0 months; HR 0.64), with grade 3+ adverse events in 56.3% vs 52.4%. Funder: 'Funded by Sanofi'. Conflicts: two co-authors are Sanofi employees (A. Ozatilgan, Sanofi Global Medical Oncology, Cambridge MA; C. Geffriaud-Ricouard, Sanofi Europe Medical Oncology, Paris), listed in the author affiliations. Maker: Sanofi (Jevtana). Comparator: abiraterone or enzalutamide (active alternative), not placebo. Study type: randomized trial.
